Mirador Capital Partners LP Grows Stake in LifeMD, Inc. (NASDAQ:LFMD)

Mirador Capital Partners LP boosted its holdings in LifeMD, Inc. (NASDAQ:LFMD - Free Report) by 139.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 106,059 shares of the company's stock after buying an additional 61,731 shares during the quarter. Mirador Capital Partners LP owned 0.24% of LifeMD worth $525,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Quest Partners LLC bought a new stake in shares of LifeMD in the second quarter worth approximately $31,000. nVerses Capital LLC bought a new stake in LifeMD in the 3rd quarter worth approximately $46,000. Intech Investment Management LLC bought a new stake in LifeMD in the 3rd quarter worth approximately $54,000. CWM LLC purchased a new stake in LifeMD during the 3rd quarter valued at $59,000. Finally, SG Americas Securities LLC bought a new position in shares of LifeMD during the 3rd quarter valued at $70,000. Institutional investors own 35.52% of the company's stock.

Insider Buying and Selling at LifeMD

In other news, CEO Justin Schreiber sold 25,000 shares of the firm's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $6.52, for a total transaction of $163,000.00. Following the sale, the chief executive officer now directly owns 2,728,715 shares in the company, valued at $17,791,221.80. This trade represents a 0.91 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 15.97% of the company's stock.

LifeMD Price Performance

Shares of NASDAQ:LFMD traded down $0.08 during mid-day trading on Thursday, reaching $4.82. 238,888 shares of the company traded hands, compared to its average volume of 619,609. LifeMD, Inc. has a 52 week low of $3.99 and a 52 week high of $12.88. The firm has a market cap of $208.75 million, a PE ratio of -7.53 and a beta of 1.49. The company's 50 day moving average price is $5.61 and its 200-day moving average price is $5.48.

Wall Street Analyst Weigh In

A number of analysts recently commented on LFMD shares. Mizuho assumed coverage on LifeMD in a research report on Wednesday, December 4th. They set a "neutral" rating and a $7.00 price objective for the company. KeyCorp reduced their price target on shares of LifeMD from $10.00 to $7.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Lake Street Capital assumed coverage on shares of LifeMD in a research note on Tuesday, December 10th. They issued a "buy" rating and a $12.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $12.00 target price on shares of LifeMD in a research report on Monday, November 11th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $15.00 price target on shares of LifeMD in a research report on Friday, September 20th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, LifeMD currently has an average rating of "Moderate Buy" and a consensus price target of $11.14.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.